IQM-QUANTUM-COMPUTERS
12.11.2021 11:02:06 CET | Business Wire | Press release
As part of its long-term growth strategy, IQM Quantum Computers announces the operation of its new state-of-the-art fabrication and cryogenic characterization facility, which will expand its quantum processor production capacity. This new facility is situated close to its headquarters and quantum labs in Espoo, Finland and marks the company’s largest investment to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211112005477/en/
Today, IQM has started its pilot line and will expand with further fabrication lines in the future. These facilities will substantially accelerate the company’s quantum processor design cycle and increase its microelectronics fabrication capacity to keep pace with the dramatic technology shifts underway within national quantum programs, high-performance computing centers, and increasing demand from the industrial customers. In addition, the facilities will ensure the highest industry-level quality required for quantum computing.
“We continue to see increasing demand for our on-premises quantum computers across Europe and globally. Today, we are announcing our largest-ever investment in production to dramatically increase our quantum processor supply and build quantum computers of the future,” said Dr. Jan Goetz, CEO and co-founder of IQM Quantum Computers.
“This investment in equipment, infrastructure and our workforce increases our fabrication, new material research, 3D integration and product delivery capabilities. Today, we’ve started the first phase of our fabrication facility and we plan to continuously learn, and invest in further expansion.”
The pilot line at this facility will be ramped-up over the coming months, and it is expected to reach maximum production capacity during 2022.
This new facility will create high-tech job opportunities and serve as an advanced manufacturing workforce-development initiative. IQM plans to partner with the Finnish and European ecosystems and prepare its workforce for the long-term, high-quality employment and growth opportunities the new facilities will present.
This is another strategic step to strengthen IQM’s position as the category leader for on-premises quantum computers in Europe and provides a strong competitive advantage over other quantum startups.
Facts:
- Location: Espoo, Finland
- Investment: € 20 Million
- Area: 560 m2
About IQM Quantum Computers:
IQM is the Pan-European category leader in building quantum computers.
IQM delivers on-premises quantum computers for supercomputing centers and research laboratories and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique, application-specific, co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium was awarded a project to commercialize application-specific quantum processors by the German Ministry of Education and Research in February 2021.
IQM has raised €71 million from private and public funding and has offices in Espoo, Finland; Munich, Germany; and Bilbao, Spain.
For more information, visit www.meetiqm.com .
Registered office:
IQM Finland Oy
Keilaranta 19
02150 Espoo
Finland
www.meetiqm.com
You can watch the complete recording of the launch event here: https://youtu.be/EUvAfl7a0Vs
View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005477/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom